Lisa K Stamp1, Rufus Turner1, Irada S Khalilova1, Mei Zhang1, Jill Drake1, Louisa V Forbes1, Anthony J Kettle2. 1. Department of Medicine, Department of Pathology, Centre for Free Radical Research, University of Otago, and Clinical Pharmacology Canterbury Health Laboratories, Christchurch, New Zealand. 2. Department of Medicine, Department of Pathology, Centre for Free Radical Research, University of Otago, and Clinical Pharmacology Canterbury Health Laboratories, Christchurch, New Zealand. tony.kettle@otago.ac.nz.
Abstract
OBJECTIVES: The aims of this study were to establish whether, in patients with gout, MPO is released from neutrophils and urate is oxidized to allantoin and if these effects are attenuated by allopurinol. METHODS:MPO, urate, allantoin and oxypurinol were measured in plasma from 54 patients with gout and 27 healthy controls. Twenty-three patients had acute gout, 13 of whom were receiving allopurinol, and 31 had intercritical gout, 20 of whom were receivingallopurinol. Ten additional gout patients had samples collected before and after 4 weeks of allopurinol. RESULTS:Plasma MPO and its specific activity were higher (P < 0.05) in patients with acute gout not receivingallopurinol compared with controls. MPO protein in patients' plasma was related to urate concentration (r = 0.5, P < 0.001). Plasma allantoin was higher (P < 0.001) in all patient groups compared with controls. In controls and patients not receiving allopurinol, allantoin was associated with plasma urate (r = 0.62, P < 0.001) and MPO activity (r = 0.45, P < 0.002). When 10 patients were treated with allopurinol, it lowered their plasma urate and allantoin (P = 0.002). In all patients receiving allopurinol, plasma allantoin was related to oxypurinol (r = 0.65, P < 0.0001). Oxypurinol was a substrate for purified MPO that enhanced the oxidation of urate. CONCLUSION: Increased concentrations of urate in gout lead to the release of MPO from neutrophils and the oxidation of urate. Products of MPO and reactive metabolites of urate may contribute to the pathology of gout and hyperuricaemia. At low concentrations, oxypurinol should reduce inflammation, but high concentrations may contribute to oxidative stress.
RCT Entities:
OBJECTIVES: The aims of this study were to establish whether, in patients with gout, MPO is released from neutrophils and urate is oxidized to allantoin and if these effects are attenuated by allopurinol. METHODS:MPO, urate, allantoin and oxypurinol were measured in plasma from 54 patients with gout and 27 healthy controls. Twenty-three patients had acute gout, 13 of whom were receiving allopurinol, and 31 had intercritical gout, 20 of whom were receiving allopurinol. Ten additional goutpatients had samples collected before and after 4 weeks of allopurinol. RESULTS: Plasma MPO and its specific activity were higher (P < 0.05) in patients with acute gout not receiving allopurinol compared with controls. MPO protein in patients' plasma was related to urate concentration (r = 0.5, P < 0.001). Plasma allantoin was higher (P < 0.001) in all patient groups compared with controls. In controls and patients not receiving allopurinol, allantoin was associated with plasma urate (r = 0.62, P < 0.001) and MPO activity (r = 0.45, P < 0.002). When 10 patients were treated with allopurinol, it lowered their plasma urate and allantoin (P = 0.002). In all patients receiving allopurinol, plasma allantoin was related to oxypurinol (r = 0.65, P < 0.0001). Oxypurinol was a substrate for purified MPO that enhanced the oxidation of urate. CONCLUSION: Increased concentrations of urate in gout lead to the release of MPO from neutrophils and the oxidation of urate. Products of MPO and reactive metabolites of urate may contribute to the pathology of gout and hyperuricaemia. At low concentrations, oxypurinol should reduce inflammation, but high concentrations may contribute to oxidative stress.
Authors: Lenka Hasikova; Marketa Pavlikova; Hana Hulejova; Petr Kozlik; Kveta Kalikova; Aparna Mahajan; Martin Herrmann; Blanka Stiburkova; Jakub Zavada Journal: Rheumatol Int Date: 2019-07-31 Impact factor: 2.631
Authors: Arrigo F G Cicero; Federica Fogacci; Raffaele Ivan Cincione; Giuliano Tocci; Claudio Borghi Journal: Med Princ Pract Date: 2020-10-09 Impact factor: 1.927
Authors: Rufus Turner; Stephen O Brennan; Louisa V Ashby; Nina Dickerhof; Melanie R Hamzah; John F Pearson; Lisa K Stamp; Anthony J Kettle Journal: J Biol Chem Date: 2018-11-01 Impact factor: 5.157
Authors: Li-Ming Gan; Maria Lagerström-Fermér; Hans Ericsson; Karin Nelander; Eva-Lotte Lindstedt; Erik Michaëlsson; Magnus Kjaer; Maria Heijer; Carl Whatling; Rainard Fuhr Journal: Br J Clin Pharmacol Date: 2019-02-18 Impact factor: 4.335
Authors: Yessica Zamudio-Cuevas; Karina Martínez-Flores; Javier Fernández-Torres; Yahir A Loissell-Baltazar; Daniel Medina-Luna; Ambar López-Macay; Javier Camacho-Galindo; Cristina Hernández-Díaz; Mónica G Santamaría-Olmedo; Edgar Oliver López-Villegas; Francesca Oliviero; Anna Scanu; Jorge Francisco Cerna-Cortés; Marwin Gutierrez; Carlos Pineda; Alberto López-Reyes Journal: Arthritis Res Ther Date: 2016-05-21 Impact factor: 5.156